APTA Therapeutics is a clinical stage biopharmaceutical company focused on the development of innovative therapies that target regulatory autoantibody associated diseases.
Regulatory autoantibodies (RAbs) are a natural class of antibodies that help to maintain immune balance. Some RAbs are able to bind to G protein-coupled receptors (GPCRs) and modulate their signaling. They are known as RAb-GPCRs and their dysregulation or excessive production can potentially lead to the development of diseases.
In recent years, dysregulated RAb-GPCRs have become a rapidly growing area of research, identifying them as potential key drivers of various diseases, including autoimmune disorders, cardiovascular disease, neuropsychiatric syndromes, and post-viral sequelae.
Our lead drug candidate, rovunaptabin, specifically binds to RAbs and prevents them from activating GPCRs with high precision. This mechanism may also lead to a reduction in further production of RAbs.
APTA Therapeutics is a pioneering clinical-stage biopharmaceutical company dedicated to transforming the treatment of diseases caused by regulatory autoantibodies.
Regulatory autoantibodies binding to G protein-coupled receptors are increasingly recognized as potential key drivers of various diseases.
APTA Therapeutics is currently focused on the clinical development of rovunaptabin in heart failure and in post viral infectious diseases.